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Abstract Insulin stimulates its own secretion and synthesis by
pancreatic L-cells. Although the exact molecular mechanism in-
volved is unknown, changes in L-cell insulin signalling have been
recognized as a potential link between insulin resistance and its
impaired release, as observed in non-insulin-dependent diabetes.
However, insulin resistance is also associated with elevated plas-
ma levels of free fatty acids (FFA) that are well known modu-
lators of insulin secretion by pancreatic islets. This information
led us to investigate the e¡ect of FFA on insulin receptor signal-
ling in pancreatic islets. Exposure of pancreatic islets to palmi-
tate caused up-regulation of several insulin-induced activities
including tyrosine phosphorylation of insulin receptor and
pp185. This is the ¢rst evidence that short exposure of these
cells to 100 WM palmitate activates the early steps of insulin
receptor signalling. 2-Bromopalmitate, a carnitine palmitoyl-
CoA transferase-1 inhibitor, did not a¡ect the e¡ect of the fatty
acid. Cerulenin, an acylation inhibitor, abolished the palmitate
e¡ect on protein levels and phosphorylation of insulin receptor.
This result supports the proposition that protein acylation may
be an important mechanism by which palmitate exerts its mod-
ulating e¡ect on the intracellular insulin signalling pathway in
rat pancreatic islets.
. 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
The process of glucose-induced insulin secretion in the pan-
creatic L-cell is dependent on the two signalling pathways. The
KATP channel-dependent pathway acts via elevation of ATP
or the ATP/ADP ratio, which closes the ATP potassium chan-
nel (KATP), increasing the intracellular potassium concentra-
tion that leads to membrane depolarization [1]. This phenom-
enon induces the opening of the voltage-sensitive calcium
channels provoking a rapid increase in calcium in£ux and in
the intracellular calcium concentration that triggers insulin
release [2]. The glucose-induced insulin secretion also activates
a KATP channel-independent pathway, which involves tyrosine
protein kinases that control the activities of diverse enzymes
and proteins in islet cells [3,4]. Insulin has been demonstrated
to activate tyrosine kinase-linked cell surface receptors in
L-cells and its intracellular signalling transduction pathway
[5]. The insulin receptor (IR) L-subunit, which contains an
intrinsic tyrosine kinase activity, undergoes tyrosyl autophos-
phorylation and is activated after insulin binding. The major
early steps of the insulin signalling pathway involve tyrosine
phosphorylation of IR substrates 1 and 2 (IRS-1 and IRS-2)
[6,7]. Tyrosine phosphorylation of IRS proteins transduces
signalling pathways that regulate essential cellular processes
including intermediary metabolism, gene expression, growth
and di¡erentiation of pancreatic islets [8,9]. Recent studies
have shown that activation of the IR in L-cells mediates not
only insulin secretion but also insulin gene transcription [10^
13]. In insulin-resistant tissues or cells, de¢ciencies have been
shown in several steps of the signalling, including autophos-
phorylation of the IR in response to insulin binding [14,15].
E¡ects of free fatty acids (FFA) on pancreatic L-cells have
long been recognized. Acute exposure of the pancreatic L-cell
to FFA results in an increase of insulin release, whereas a
chronic exposure results in desensitization and suppression
of secretion [16,17]. These observations raise the possibility
that fatty acids may directly modulate insulin secretion in
vivo and thus contribute to the coexistence of hyperlipidemia
and hyperinsulinemia that is seen in insulin resistance states
[18^20]. Although fatty acid oxidation is necessary [17,21], the
complete mechanism by which these metabolites modulate
insulin secretion remains largely unclear.
We examined if the increase of insulin secretion induced by
acute administration of FFA is related to modulation of the
early steps of insulin action. The phosphorylation status and
expression of IR and IRS-1 in freshly isolated rat pancreatic
islets incubated with palmitate were determined. The e¡ect of
2-bromopalmitate (a carnitine palmitoyl transferase-1 (CPT-1)
inhibitor) and cerulenin (an inhibitor of protein acylation) was
tested to establish the possible mechanism involved.
2. Materials and methods
2.1. Materials
Reagents for sodium dodecyl sulfate^polyacrylamide gel electro-
phoresis (SDS^PAGE) and immunoblotting were obtained from
Bio-Rad (Richmond, CA, USA). Trizma, aprotinin, dithiothreitol,
Triton X-100, glycerol, Tween 20, sodium palmitate, cerulenin and
bovine serum albumin (BSA, fraction V) were obtained from Sigma
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(St. Louis, MO, USA). 2-Bromopalmitate was from Aldrich (Stein-
heim, Germany). Protein A-Sepharose 6 MB was obtained from Phar-
macia (Uppsala, Sweden). Immunoblot ECL chemiluminescence de-
tection kit was from Amersham Pharmacia Biotech (Buckingham-
shire, UK) and nitrocellulose paper (0.45 Wm) was from Bio-Rad
(Hercules, CA, USA). Antibodies against phosphotyrosine, IR, and
IRS-1 were from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
2.2. Animals
Female albino rats weighing 250^400 g were kept under standard
lighting conditions (12 h light/dark cycle) at a temperature of
23L 1‡C, in groups of ¢ve, and were allowed access to standard ro-
dent chow and water ad libitum until studied. The study was ap-
proved by the Ethical Committee of the Institute of Biomedical Sci-
ences, University of Sa‹o Paulo.
2.3. Isolation of pancreatic islets
The islets were isolated by collagenase digestion of the pancreas
following a method previously described [22]. Krebs bu¡er containing
115 mM NaCl, 5 mM KCl, 24 mM NaHCO3, 1 mM CaCl2 and 1 mM
MgCl2 was used for isolation and pooling of the islets.
2.4. E¡ect of palmitate, 2-bromopalmitate and cerulenin on insulin
signalling proteins
Groups of 200^300 islets were incubated at 37‡C in Krebs^bicar-
bonate bu¡er containing 5.6 mM glucose equilibrated with a mixture
of 95% O2/5% CO2, pH 7.4, in the absence or presence of palmitate in
the concentrations described in the ¢gure legends and/or 2-bromopal-
mitate (100 WM) for 30 min and/or preincubation with cerulenin (30
Wg/ml). Palmitate and 2-bromopalmitate were dissolved in ethanol
before addition into the incubation medium to form an emulsi¢ed
fatty acid solution. The ¢nal ethanol concentration in this fatty acid
solution was 0.5%. Preliminary experiments established that 0.5%
ethanol has no e¡ect on basal insulin release [23]. At the end of the
experiments, the islets were transferred to an Eppendorf tube contain-
ing 80 Wl extraction bu¡er (100 mM Trizma, 1% SDS, 100 mM so-
dium pyrophosphate, 100 mM sodium £uoride, 10 mM EDTA and 10
mM sodium vanadate), homogenized using a Polytron (Brinkmann
Instruments, Westbury, NY, USA), and boiled for 5 min. The extracts
were then centrifuged at 12 000 rpm at 4‡C for 20 min to remove
insoluble material. Protein determination in the supernatants was per-
formed by the Bradford dye method using the Bio-Rad reagent [24].
2.5. Electrophoresis and immunoblotting
The proteins were treated with Laemmli sample bu¡er [25] contain-
ing dithiothreitol and boiled for 5 min before loading onto 8% SDS^
PAGE in a Bio-Rad miniature slab gel apparatus. Similar-sized ali-
quots (60 Wg) were subjected to SDS^PAGE. The electrotransfer of
proteins from the gel to nitrocellulose was performed for 1 h at 120 V
(constant) in a Bio-Rad miniature transfer apparatus. Non-speci¢c
protein binding to the nitrocellulose was reduced by preincubation
for 1 h at 22‡C in blocking bu¡er (5% non-fat dry milk, 10 mM
Trizma, 150 mM NaCl, and 0.02% Tween 20). The nitrocellulose
membranes were incubated for 4 h at 22‡C with antibodies against
phosphotyrosine, IR, and IRS-1 diluted in blocking bu¡er with 3%
non-fat dry milk, and then washed for 60 min in blocking bu¡er
without milk. The blots were subsequently incubated with peroxi-
dase-conjugated secondary antibody for 1 h, and processed for en-
hanced chemiluminescence to visualize the immunoreactive bands.
For reprobing, membranes were stripped, washed, and incubated
with either anti-IR polyclonal antibody or anti-IRS-1 polyclonal anti-
body. Band intensities were quanti¢ed by optical densitometry (Scion
Image-Release Beta 3b, NIH, Bethesda, MD, USA) of the developed
autoradiographs.
2.6. Statistical analysis
Data are presented as the meanLS.E.M. Statistical signi¢cant dif-
ferences between groups were analyzed using Student’s unpaired
t-test. The level of signi¢cance was set at P6 0.05.
3. Results
After the incubation of the islets with Krebs^bicarbonate
bu¡er containing 5.6 mM glucose, in the absence or presence
of di¡erent concentrations of palmitate (1^100 WM) for 30
min, the islets were homogenized and the total islet extracts
were analyzed by immunoblotting using an anti-phosphotyr-
osine antibody. An increase in tyrosine phosphorylation of IR
and pp185 (IRS-1/-2) even at low palmitate concentrations
such as 1 WM was detected. The densitometry of three distinct
experiments is represented in the graph bars (Fig. 1A^C).
The same membranes were reprobed with anti-IR and anti-
IRS-1. We detected an augmentation in IR protein level to
148L 12% (P6 0.05) in palmitate-treated islets (Fig. 2A). The
same approach was used to identify IRS-1 protein level. Sim-
ilar to IR, the IRS-1 protein level increased to 194L 26%
(P6 0.05) in the palmitate group (Fig. 2B).
In order to investigate if the palmitate-induced tyrosine
phosphorylation and increased protein levels of IR and IRS-
1 were due to palmitate oxidation, the islets were incubated
with 2-bromopalmitate, an inhibitor of CPT-1. The exposure
of the islets to palmitate plus 2-bromopalmitate resulted in a
similar increase of tyrosine phosphorylation status in IR (by
40L 14%, P6 0.05) and in pp185 (by 82L34%, P6 0.05) to
that observed when palmitate was added alone. The incuba-
tion of pancreatic islets with 2-bromopalmitate alone did not
change the phosphorylation status of IR and pp185 when
compared with the control (without fatty acid) (Fig. 3A,B).
Total islet extracts were also analyzed by immunoblotting
Fig. 1. Palmitate-induced tyrosine phosphorylation of IR and pp185
in isolated pancreatic islets of normal rats. Groups of 200^300 islets
were incubated with 5.6 mM glucose in the presence of 1, 10 and
100 WM palmitate for 30 min. Afterwards, the islets were homoge-
nized in extraction bu¡er at 100‡C for 5 min. After centrifugation,
aliquots with the same amount of proteins were resolved on 8%
SDS^PAGE, transferred to nitrocellulose, and detected with anti-
phosphotyrosine antibody (A). Scanning densitometry was per-
formed on autoradiograms from three distinct experiments to deter-
mine IR (B) and pp185 (C) tyrosine phosphorylation. The values
are expressed as meanLS.E.M. *P6 0.05 compared with 5.6 mM
glucose.
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using anti-IR and anti-IRS-1 antibodies (Fig. 3C,D). The ex-
posure of pancreatic islets to palmitate plus 2-bromopalmitate
had the same e¡ect as palmitate alone. Similar to what was
observed for tyrosine phosphorylation, the protein levels of
IR and IRS-1 remained unchanged in the pancreatic islets
incubated with 2-bromopalmitate alone when compared to
control.
To determine if protein acylation could be involved in the
palmitate-induced IR and IRS-1 tyrosine phosphorylation
and increased protein levels, the e¡ect of cerulenin, an acyla-
tion inhibitor, was tested. Preincubation with cerulenin at 30
Wg/ml for 30 min abolished the IR and pp185 tyrosine phos-
phorylation induced by 100 WM palmitate to 48L 5%
(P6 0.05; Fig. 4A) and to 78L5% (P6 0.05; Fig. 4B) respec-
tively. The increased protein levels of IR and IRS-1 induced
by palmitate were also abolished by preincubation of pancre-
atic islets with cerulenin (Fig. 4C,D). Incubation with cerule-
nin alone had no e¡ect either on tyrosine phosphorylation or
on protein levels of IR and IRS-1 when compared to control
(data not shown).
4. Discussion
Evidence is presented herein that palmitate induces tyrosine
phosphorylation of some insulin signalling molecules in incu-
bated rat pancreatic islets and also increases their protein
levels. Short-term incubation with palmitate in medium con-
taining 5.6 mM glucose induced an increase in tyrosine phos-
phorylation status and in protein levels of IR and IRS-1 in
Fig. 2. Palmitate e¡ects on protein levels of IR and IRS-1 in iso-
lated pancreatic islets of normal rats. Groups of 200^300 islets were
incubated with 5.6 mM glucose in the absence (C) or presence of
100 WM palmitate (P) for 30 min. The islets were treated as de-
scribed in the legend of Fig. 1, except that the immunoblot was
done using anti-IR (A) and anti-IRS-1 (B) antibodies. Scanning
densitometry was performed on autoradiograms from three distinct
experiments to determine IR (A) and IRS-1 (B) protein levels. The
values are expressed as meanLS.E.M. *P6 0.05.
Fig. 3. E¡ects of inhibition of palmitate oxidation on tyrosine phos-
phorylation and protein levels of IR and IRS-1. In order to analyze
if the e¡ects of palmitate-induced tyrosine phosphorylation and in-
creased protein levels of IR and IRS-1 were due to palmitate oxida-
tion, 2-bromopalmitate, an inhibitor of CPT-1, was used. 100 WM
2-bromopalmitate was incubated in the absence (B) or presence of
100 WM palmitate (B+P) for 30 min. The islets were homogenized
and subjected to SDS^PAGE as described in Section 2. A and B
are representative of immunoblots using anti-phosphotyrosine anti-
body. C is a representative blot with anti-IR antibody and D is a
representative blot with anti-IRS-1 antibody. Values are expressed
as meansLS.E.M. of nine experiments. *P6 0.05.
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Fig. 4. E¡ects of inhibition of palmitate acylation on tyrosine phos-
phorylation and protein levels of IR and IRS-1. In order to analyze
if the e¡ects of palmitate-induced tyrosine phosphorylation and in-
creased protein levels of IR and IRS-1 were due to protein acyla-
tion, the islets were treated with cerulenin (Ce), an acylation inhibi-
tor, for 30 min prior to palmitate (P) incubation. The islet proteins
were isolated as described in Section 2 and in the legends of the
previous ¢gures. A and B are representative of immunoblots using
anti-phosphotyrosine antibody. C is a representative blot with anti-
IR antibody and D is a representative blot with anti-IRS-1 anti-
body. Values are expressed as meansLS.E.M. of ¢ve experiments.
*P6 0.05.
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isolated rat pancreatic islets. These e¡ects may have a biolog-
ical signi¢cance, since IR autophosphorylation has been cor-
related with insulin secretion [26].
In L-cells, the cytoplasmic fatty acids are converted to
Long-chain acyl-CoA (LC-CoA) by acyl-CoA synthase. In
basal conditions, the LC-CoA molecules are transported
into the mitochondria via CPT-1, where L-oxidation takes
place. High levels of glucose inhibit this process and raise
the cytoplasmic content of LC-CoA [27,28]. This action oc-
curs due to the elevated malonyl-CoA concentration formed
from glucose metabolism. The activity of CPT-1 is inhibited
by high levels of malonyl-CoA, leading to decreased oxidation
of fatty acids and an increase in LC-CoA in the cytosol
[29,30]. It has been suggested that LC-CoA may act as an
e¡ector molecule in the KATP channel-independent pathway
of glucose-induced insulin secretion [2]. LC-CoA controls sev-
eral L-cell functions, including activation of certain types of
protein kinase C, modulation of ion channels, and gene ex-
pression [2,20,27]. Fatty acids also a¡ect the late stages of the
secretory cascade probably at the level of Ca2þ entry into the
L-cell or at a point distal to this step (perhaps at the stage of
fusion of the insulin granule with the plasma membrane or
exocytosis). These actions may result in an e⁄cient L-cell
functioning and insulin release.
In spite of the information above, the precise mechanism
involved in the e¡ect of FFA on insulin secretion remains
unknown. An e¡ect of fatty acids on signalling molecules
such as IR, IRS-1 and protein kinase C has been proposed
in skeletal muscle cells but little is known about this molecular
mechanism in pancreatic islets [31]. We showed herein for the
¢rst time that palmitate stimulates the early steps of the in-
sulin signalling pathway in pancreatic islets. Exposure of these
cells to palmitate for 30 min showed up-regulation of some
insulin-induced activities including tyrosine phosphorylation
of IR. These ¢ndings are consistent with reports describing
that FFA improve insulin sensitivity [16,32] and play a critical
role to modulate the stimulatory e¡ect of glucose on insulin
release [17,33]. The increased IR phosphorylation in isolated
pancreatic islets at 5.6 mM glucose by palmitate may play a
role in the cellular mechanism by which this fatty acid mod-
ulates glucose-induced insulin secretion. Using the CPT-1 in-
hibitor 2-bromopalmitate, we could detect that palmitate-in-
duced tyrosine phosphorylation and increased protein levels
of IR and IRS-1 were not a result of fatty acid oxidation.
Several Src family members can be acylated and palmitate
regulates their membrane binding and subcellular distribution
[34^37]. The group of Src family tyrosine kinases is modi¢ed
by saturated fatty acyl chains, i.e. myristoyl and palmitoyl
moieties. Palmitoyl-CoA can attach posttranslationally to
protein cysteine residues through a thioester linkage in a re-
versible modi¢cation with dynamically regulated cycles of acy-
lation and deacylation. The role of protein acylation includes
direction of proteins to appropriate membrane sites, stabiliz-
ing protein^protein interactions, and regulating enzyme activ-
ities in mitochondria [38]. Palmitoylation of receptor tyrosine
kinases is of particular importance since these proteins are
proximal components that transduce diverse receptor-medi-
ated signalling pathways. Modulation of their functional ac-
tivity by palmitate may a¡ect the downstream signalling path-
way and target gene expression [39]. Cerulenin abolished the
palmitate e¡ect on protein levels and phosphorylation of IR
and IRS-1. This result supports the proposition that protein
acylation is involved in the activation of the early steps of
insulin signalling in isolated pancreatic islets induced by pal-
mitate.
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